Suitable Autologous Vein Research Articles

Eleven-year experience with tibiotibial bypass: An unusual but effective solution to distal tibial artery occlusive disease and limited autologous vein

Purpose: The absence of sufficient length of suitable autologous vein occasionally prohibits the treatment of severe distal lower extremity arterial occlusive disease with a standard distal bypass originating from the common femoral artery. During the past 11 years, we have therefore selectively performed short distal bypasses originating from the infrapopliteal arteries in patients with limb-threatening ischemia and occlusive lesions limited to the distal tibial and peroneal arteries. This report summarizes our experience with these tibial artery based distal bypasses.Methods: Forty-two distal lower extremity arterial bypasses originating from infrapopliteal arteries in 41 patients were performed over an 11-year period. Autologous vein was used as the bypass conduit in all cases. Extensions from a more proximal bypass were excluded.Results: The primary patency rate of these tibiotibial bypasses was 77% at 1 year and 62% after 5 years. The limb salvage rate after 5 years was 74%. The perioperative mortality rate was low (2%), but the 5-year patient survival rate (64%) was similar to that with more standard lower extremity arterial reconstructive procedures.Conclusions: Tibiotibial bypass is an effective limb salvage procedure in carefully selected patients with distal tibial artery occlusive disease and limited autologous vein. It offers a durable means of distal revascularization in circumstances in which a standard operation might not be desirable or possible.

Three years experience with denaturated venous homografts as an arterial substitute: A clinical, pathological and immunological study

Over a three-year-period 105 peripheral arterial reconstructions were performed using a denaturated venous homograft in a group of patients with no suitable autologous vein. A retrospective analysis has been carried out to investigate the patency rate of this graft. After three years 64% of all grafts are functioning well (according to the Life Table Method, Kaplan & Meyer). No significant differences in patency rates were found between reversed autologous veins and the material tested in this study but analysis of grafts removed after failure showed obstruction due to thrombosis or aneurysmal dilatation. No evidence of an immune response to the grafts was seen.

Seven-year follow-up of expanded polytetrafluoroethylene (PTFE) femoropopliteal bypass grafts.

Expanded polytetrafluoroethylene (PTFE) grafts have proven to be an acceptable short-term alternative for femoropopliteal reconstruction in those patients without suitable autologous saphenous vein. One hundred and twenty-seven femoropopliteal arterial bypass operations utilizing PTFE grafts were performed in 105 patients. Seven-year follow-up is now available for 20 grafts, 6-year follow-up for 47 grafts, and 5-year follow-up for 62 grafts. Graft occlusion was determined by angiography, Doppler assessment, loss of previously palpable pulses, or return of symptoms. Thirty nonocclusive graft losses were due to death, infection, aneurysm, amputation, or proximal occlusive disease. Overall cumulative patency rate, according to occlusive criteria alone and calculated by the life-table method, was 74% at 6 months, 63% at 1 year, 48% at 3 years, 40% at 5 years, and 35% at 7 years. Excluding early bypass failures (less than 1 year patency), 75% of grafts were patent at 3 years, 63% at 5 years, and 55% patent 7 years following operation. Diabetes mellitus was associated with a significantly lower patency rate. Patency rates were not adversely affected by graft diameter, distal popliteal anastomotic site, number of patent runoff vessels, preoperative symptoms, or prior arterial reconstruction. In patients without suitable autologous saphenous vein, the PTFE graft has proven to be a durable and dependable long-term alternative for femoropopliteal reconstruction.

Nonanastomotic aneurysms in venous homologous grafts and bovine heterografts in femoropopliteal bypasses

In the absence of a suitable autologous vein for a long distal femoropopliteal bypass, the homologous vein appears to be a good substitute. However, the patency rate after one year is less than 50 per cent and nonanastomotic aneurysms occurred in one third of our patients followed for more than one year. These two complications may be related to an immune response which may be lessened by preservation of the graft in the frozen state. Bovine heterografts function well when placed subfascially for femoropopliteal bypasses ending above the knee. Failure rate is high when the distal end of the graft extends across the knee joint. In our experience nonanastomotic aneurysms have developed in 50 per cent of patent grafts followed for more than one year, although other surgeons have reported an incidence of only 3 to 20 per cent. In the follow-up of twenty-three venous homografts and twenty bovine heterografts placed as femoropopliteal bypasses, eight nonanastomotic aneurysms appeared and required replacement. This occurrence was noted in more than 33 per cent of grafts patent beyond one year. When an adequate autologous vein is not available, the composite Dacron-vein graft is the best substitute.